Synlogic stock analysis
Synlogic (0A8U) Share Price & Analysis
0A8U Stock Chart & Stats
- Day’s Range
- $1.00 - $1.04
- 52-Week Range
- $0.54 - $1.79
- Previous Close
- $1.10
- Volume
- N/A
- Average Volume (3M)
- 141
- Market Cap
- $12.25M
- Enterprise Value
- $4.96M
- Total Cash (Recent Filing)
- $11.56M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.36
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
Debt falling to zero materially reduces fixed financial obligations and refinancing exposure, while positive equity provides a cushion for continued development. This improves financial flexibility and lowers balance-sheet risk, although it does not by itself establish operating self-sufficiency.
Lower Cash Burn
The sharp reduction in operating cash burn shows materially better cost discipline and extends the usefulness of available funding. This can support continued research execution with fewer resources, improving resilience even though free cash flow remains negative.
Merger Financing And Development Runway
The merger and substantial private placement could provide the capital needed to advance Phase 2 programs and sustain operations through 2029. A longer funded runway supports clinical execution and reduces immediate financing pressure while development milestones are pursued.
Bears Say
No Commercial Revenue
The absence of recurring commercial revenue leaves Synlogic dependent on partnerships, financing, or other external sources to fund development. It also limits earnings visibility and operating leverage, making future performance highly dependent on successful clinical progress.
Persistently Negative Free Cash Flow
Negative free cash flow means the company is not yet funding its operations internally, despite substantially improved cash discipline. Continued dependence on existing cash or external capital can constrain strategic flexibility and expose development plans to financing requirements.
Shrinking Asset Base And Negative Returns
The substantial contraction in total assets alongside persistently negative returns indicates ongoing erosion of the company’s financial scale. This weakens the balance-sheet foundation available for development and suggests cost reductions have not yet produced durable economic returns.
Synlogic News
0A8U FAQ
What was Synlogic’s price range in the past 12 months?
What is Synlogic’s market cap?
When is Synlogic’s upcoming earnings report date?
How were Synlogic’s earnings last quarter?
Is Synlogic overvalued?
Does Synlogic pay dividends?
What is Synlogic’s EPS estimate?
How many shares outstanding does Synlogic have?
What happened to Synlogic’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Synlogic?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mary Beth Dooley
- Employees
- 1
- Website
- www.synlogictx.com
- Address
- PO Box 30, Winchester, MA, 01890, US
Synlogic (0A8U) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 4 | 8 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 8 | 0 | 4 |









